Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 9

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 9
---
30, 2025,
and had stockholders’ equity and working capital of approximately $7.0 million at September 30, 2025.

Historically,
the Company has been primarily engaged in developing Telomir-1. During these activities, the Company sustained substantial losses. The
Company’s ability to fund ongoing operations and future clinical trials required for FDA approval is dependent on the Company’s
ability to obtain significant additional external funding in the near term. Since inception, the Company has financed its operations
through its initial public offering in February 2024, additional equity financings in 2025, and related party financings-see Note 4.
Additional sources of financing will be required by the Company to continue operations and its Telomir-1 programs. However, there can
be no assurance that any fundraising will be achieved on commercially reasonable terms, if at all.

    8

As
of the date of filing this report, the Company will continue to generate losses and have insufficient cash and cash equivalents on hand
to support its operations for at least the 12 months following the date the financial statements are issued. These factors raise substantial
doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this report.
Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise
additional debt and/or equity capital. The Company is seeking to raise more capital through additional debt and/or equity financings
to fund our operations in the future. If the Company is unable to raise additional capital or secure additional lending in the near future,
management expects that the Company will need to curtail its operations. These financial statements do not include any adjustments related
to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the
Company be unable to continue as a going concern.

Note
3. License agreement, related party:

The
Company licenses the U.S. patent rights for the use of Telomir-1 in human applications from MIRALOGX, LLC (“MIRALOGX”), an
intellectual property development and holding company established by Jonnie R. Williams, Sr., the founder of the Company and the sole
inventor of Telomir-1.

On
August 11, 2023, (the “Effective Date”), the Company and MIRALOGX entered into an Amended and Restated Exclusive License
Agreement,